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ABSTRACT
Objectives  To investigate the inﬂ  uence of early disease-
modifying antirheumatic drug (DMARD) treatment on 
long-term functional outcome in patients with recent-
onset inﬂ  ammatory polyarthritis (IP), and the impact of 
the duration of ﬁ  rst and subsequent DMARD treatment.
Methods  642 subjects from a primary care registry 
of patients with new-onset IP, recruited 1990–4, were 
followed up for 10 years. Mean change in Health 
Assessment Questionnaire (HAQ) scores between 
baseline and 10 years were compared by time to, and 
time receiving, ﬁ  rst DMARD treatment and total time 
receiving treatment, using linear regression. Adjustment 
for time-dependent confounders and censoring was 
performed using marginal structural weights.
Results  When adjusted for baseline and subsequent 
disease severity, those treated early (<6 months 
from symptom onset) experienced a non-signiﬁ  cant 
improvement in function compared with those never 
treated (adjusted mean difference in change (adj_MDIC) 
in HAQ –0.24; 95% CI –0.58 to 0.09); and a signiﬁ  cant 
beneﬁ  t for each additional month of treatment within 
6 months of the onset of symptoms (adj_MDIC –0.10; 
95% CI –0.19 to –0.02). Patients who discontinued their 
ﬁ  rst DMARD within 6 months experienced a signiﬁ  cant 
deterioration in long-term function (adj_MDIC in HAQ 
0.28; 95% CI 0.04 to 0.52), while those who continued 
their ﬁ  rst treatment for > 3 years experienced an 
improvement (adj_MDIC in HAQ –0.37; 95% CI –0.77 to 
0.04).
Conclusions  The importance of time to, and response 
to, ﬁ  rst DMARD treatment and total duration of DMARD 
treatment in modifying the 10-year function in patients 
with IP has been demonstrated.
INTRODUCTION
A recent systematic review reported that clinical 
trials have shown the beneﬁ  t of disease-  modifying 
antirheumatic drugs (DMARDs) and steroids 
(DMARD/S) in reducing functional disability and 
disease activity in patients with rheumatoid arthritis 
(RA).1 As highlighted by subsequent commentaries 
on this review,2–5 clinical trials have limitations as 
most are of short duration (generally ≤3 years) and 
have narrow patient selection criteria. Longitudinal 
observational studies (LOS) provide an opportunity 
to examine the inﬂ  uence of treatment on long-term 
outcome and are often more generalisable than clin-
ical trials.6 However, the effect of treatment is con-
founded in LOS as those treated most intensively 
are likely to have the most severe disease.7
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A number of long-term LOS have examined the 
inﬂ  uence of DMARDs on outcome in patients with 
inﬂ  ammatory polyarthritis (IP) and its subset RA 
while adjusting for ‘confounding by indication’.8–10 
Choi et al reported a beneﬁ  t on mortality in 1240 
patients with RA treated with methotrexate 
(MTX),8 while we have previously shown that 
treating patients with IP with DMARD/S, within 6 
months of symptom onset, has a beneﬁ  cial effect on 
functional disability9 and radiological progression10 
at 5 years. Our analyses adjusted for the decision to 
prescribe the ﬁ  rst DMARD but not for subsequent 
treatment decisions. Over time, particularly in the 
long-term, potential confounders will alter, both as 
a result of the natural course of the disease and also 
in response to treatment. Therefore, to assess the 
impact of treatment over the long term, adjustment 
for these time-dependent confounders is required.
In addition to the inﬂ  uence of the timing of the 
ﬁ   rst treatment, time receiving the ﬁ  rst  treatment 
and total duration of treatment may also contrib-
ute to subsequent long-term outcome. A Swedish 
trial of 245 patients with recent-onset RA found that 
those who received their ﬁ  rst DMARD treatment for 
<2 years had lower response and remission rates than 
those who continued with treatment.11 Analysis of 
2888 patients with established RA from the ARAMIS 
database, found that the consistent use of a DMARD 
(measured as the proportion of visits at which a 
patient was taking at least one DMARD) was associ-
ated with improved functional outcome.12
Our study was conducted in an inception cohort 
of patients with IP followed up for 10 years with 
regular assessment of disease activity, physi-
cal function and treatment. We have adjusted for 
potential time-dependent confounders over the 
length of the follow-up. We aimed to investigate 
whether the beneﬁ  t of early DMARD treatment on 
functional outcome continues in the long term and 
to examine the impact of the duration of ﬁ  rst and 
subsequent DMARD treatment.
PATIENTS AND METHODS
Patients
Patients were recruited from the Norfolk Arthritis 
Register (NOAR), a primary care-based incep-
tion cohort of subjects with recent-onset IP. As 
described in detail elsewhere,13 NOAR aims to 
recruit all adults aged ≥16 years, who have swell-
ing of at least two joints persisting for at least 
4 weeks and whose symptom onset was after 
1 January 1990. The catchment area is the former 
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Norwich Health Authority, with notiﬁ  cation of cases through 
general practitioners or attendance at hospitals. Those who 
were subsequently diagnosed by a hospital consultant as hav-
ing a condition other than RA, IP, psoriatic arthritis or postviral 
arthritis were excluded. Between 1990 and 1994, 1098 subjects 
were registered with NOAR who satisﬁ  ed the above criteria. 
Fourteen subjects were excluded as they had begun DMARD 
or steroid treatment for another condition before the onset of IP 
symptoms, leaving 1084 subjects.
Data collection
Baseline
Clinical and demographic data were collected by a research nurse 
by a structured interview and clinical examination shortly after 
registration (baseline) as outlined in table 1. Detailed information 
was collected on the use of DMARDs and steroids (DMARD/S) 
and hospital attendance for patient with IP. Each subject com-
pleted the Health Assessment Questionnaire (HAQ), modiﬁ  ed 
for use in British patients.14
A blood sample was taken for rheumatoid factor (RF), anti-
cyclic citrullinated peptide antibody and C-reactive protein 
(CRP) testing. The Disease Activity Score (DAS28) was calcu-
lated from the 28 tender joint count, 28 swollen joint count and 
CRP (http://www.das-score.nl/www.das-score.nl/index.html, 
accessed 14 January 2010). Human leucocyte antigen (HLA) 
genotyping was performed as described previously.15 Subtyping 
at the HLA-DRB1 locus was performed to identify the presence 
of the shared epitope.
Follow-up
Annual assessments were carried out for 3 years, then at ﬁ  fth, sev-
enth and tenth years. Dates of starting and stopping any DMARD 
treatment since the last assessment were recorded as well as the rea-
sons for stopping (eg, inefﬁ  cacy, adverse events). Blood was taken 
for RF testing at the ﬁ  rst and second annual assessment if the subject 
had been RF negative previously. A blood sample was taken from 
all subjects at the ﬁ  fth and tenth assessments for RF and CRP testing. 
The American College of Rheumatology (ACR) 1987 classiﬁ  cation 
criteria for RA were applied both cross-sectionally at baseline and 
cumulatively at each assessment, as described previously.16
Patients attended for x-ray examinations of their hands and 
feet at the ﬁ  rst and/or second assessment, if they had already 
satisﬁ  ed the ACR criteria for RA or if the presence of erosions 
would lead to the patient satisfying them. All patients were 
invited to have x-ray examinations at the ﬁ  fth assessment and 
only those who were erosive at the ﬁ  fth were invited to the 
tenth assessment. Radiographs were scored using the Larsen 
method17 by two rheumatologists, and major disagreements 
were arbitrated by a third.18 Patients completed the Medical 
Table 1  Variables used in the marginal structural weight models
Variable Variable type
Demographics
  Age at symptom onset and at each assessment Decades
 Gender Male/Female
  Months from symptom onset at baseline and at each 
 assessment
Tertiles by assessment
  Smoking status at each assessment Never smoked/Stopped ≥ 10 years before assessment/
Stopped <10 years before assessment/Current smoker
Serological and genetic
  Anti-CCP status at baseline (Axis-Shield DIASTAT kit) <5 U/ml/≥5 U/ml
  CRP category at baseline and assessment (end point 
 immunoturbidimetric  agglutination)
≤ 10 mg/l/>10 mg/l
  RF status at baseline and by assessment (latex 
 agglutination)
<1:40/ ≥1:40
  Number of copies of the SE 0/1/2
  Homozygous for SE No/Yes
Disease activity and severity
  DAS28 score at baseline and assessment
  ACR criteria for RA cross-sectional at baseline and 
  cumulative at assessment
Not met/Met
  Number of swollen, tender and (both tender and swollen) 
  joints at baseline and assessment
Tertiles by assessment
  Presence of nodules at baseline and assessment No/Yes
  HAQ group at baseline and assessment <1/≥1 to <2/≥2
  Presence of erosions by assessment No/Yes
  Larsen score by assessment Tertiles by assessment
Physical Component Score (PCS) of SF36
  Mental Component Score (MCS) of SF36
  Diagnosed with any of 14 deﬁ  ned comorbidities by 
 assessment
No/Yes
Treatment and hospital attendance
  Attended/referred to hospital since last assessment No/Yes
  Treated with SSZ, MTX, other DMARDs and steroids at 
  baseline and by assessment
No/Yes
  Ceased treatment since last assessment or 
  by assessment due to inefﬁ  cacy or adverse event
No/Yes
  Remission by baseline and assessment No/Yes
ACR, American College of Rheumatology; anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 
28 joint count Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment 
Questionnaire; MCS, Mental Component Score; MTX, methotrexate; PCS, Physical Component Score; RA, rheumatoid 
arthritis; RF, rheumatoid factor; SE, shared epitope; SSZ, sulfasalazine.
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weight to provide a weight that produced a pseudo population 
by the tenth assessment, in which both treatment and loss to 
follow-up are independent of any of the variables considered 
to be potential time-varying confounders, enabling an unbiased 
estimate of the effect of treatment.
The logistic regression models can only include patients with 
complete data. In total, 162 840 data items were included in the 
models used to produce the weights. Of these, 6785 (4.2%) were 
missing. To impute missing data we used switching regression, 
an iterative multivariable regression technique which retains an 
element of random variation in the estimates.22 Within Stata 
these methods are incorporated within the ice and uvis programs. 
For each variable the distributions were compared with and 
without the imputed data to conﬁ  rm that the imputed data did 
not alter the distribution of any of the variables. The imputed 
data were only used in the prediction of treatment decisions 
and loss to follow-up, and were not included in the change in 
HAQ models as the marginal structural model accounts for loss 
to follow-up as well as time-dependent confounders.
RESULTS
Cohort characteristics and treatment over 
10 years of follow-up
The median age at symptom onset of the 1084 subjects was 
53 years (IQR 41–66) with two-thirds being women (table 2). 
At the baseline assessment, 493 (45.5%) subjects satisﬁ  ed the 
1987 ACR criteria for RA. After 10 years, 664 (61.3%) subjects 
continued to be followed up.
There was an increasing use of MTX, a decreasing use of sulfa-
salazine (SSZ) and a stable use of steroids with time (table 3). 
At baseline, 7% of subjects receiving a DMARD/S were receiv-
ing MTX and 60% SSZ. At the tenth year assessment, 54% 
were receiving MTX and 37% SSZ. This reﬂ  ects the changing 
management of RA during the 1990s. When restricted to those 
subjects who satisﬁ  ed the ACR criteria for RA by 10 years, the 
proportion treated was higher (eg, 64% ever treated by 10 years) 
but the pattern of the types of treatment was the same (data not 
shown).
HAQ score at baseline, 10 years and difference over 
10 years by time to, and time receiving, treatment
Of the 664 subjects with 10 years of follow-up, 642 subjects 
had completed a HAQ both at baseline and the 10-year assess-
ment; 54% of these had been treated by 10 years, of whom 35% 
were treated within 6 months of symptom onset (table 4). As 
expected patients who were judged not to require DMARD/S 
treatment by the tenth assessment had milder disease with 
lower baseline HAQ scores and smaller mean change in HAQ 
over the follow-up period (0.13, 95% CI 0.05 to 0.21) than those 
who were treated. The patients with the highest baseline HAQ 
were most likely to receive early treatment, but had no mean 
change in HAQ over the 10 years (0.00, 95% CI –0.17 to 0.17). 
Those who continued to receive their ﬁ  rst DMARD the longest, 
experienced the least deterioration in HAQ over the follow-up 
period. Patients who continued to receive their ﬁ  rst DMARD/S 
for 3 years or more experienced a deterioration in HAQ of only 
half (0.16, 95% CI 0.002 to 0.32) that seen in patients who 
stopped their ﬁ  rst DMARD within 6 months of starting it (0.35, 
95% CI 0.15 to 0.55).
After an initial improvement in the ﬁ  rst year of follow-up, 
all groups showed a steady decline in functional disability over 
the 10 years (ﬁ  gure 1). Patients who were receiving DMARD/S 
treatment at each follow-up reported poorer function than those 
Outcomes Study Short Form-36 (SF-36) (a validated generic 
health status measure),19 at the third and/or ﬁ  fth years.20
Statistical analysis
Treatment history
All analysis was conducted using Stata version 9.2 (StataCorp, 
College Station, Texas, USA). The time from symptom onset to 
the date of the ﬁ  rst treatment was categorised into three groups 
(<6 months, 6–12 months and >12 months). The duration of 
the ﬁ  rst DMARD/S treatment and total duration of treatment 
over the 10 years of follow-up, taking into account combination 
therapies, were divided into tertiles (ﬁ  rst DMARD/S treatment 
≤6 months, >6 to ≤36 months and >36 months; total duration 
≤48 months, >48 to ≤96 months, >96 months).
Outcome by 10 years and treatment
The change in HAQ score between baseline and the 10-year 
follow-up was included in a linear regression model, adjusted 
by baseline HAQ, in order to estimate the effect on long-term 
  functional disability of treatment, as well as the time to, and time 
receiving, the ﬁ  rst treatment, and total time receiving treatment. 
Patients who had never received DMARD/S were used as the 
referent group. To explore the effect of the interaction between 
time to, and time receiving, treatment the duration of the ﬁ  rst 
and any DMARD/S treatment, including combination therapies, 
were stratiﬁ  ed into the number of months of treatment in the 
ﬁ  rst 6 months since symptom onset, and the number of months 
of treatment after the ﬁ  rst 6 months since symptom onset.
Marginal structural models
We have previously adjusted for ‘confounding by indica-
tion’ using propensity scores.9 10 However, while this method 
adjusted for initiation of ﬁ  rst DMARD/S, no adjustment was 
made for subsequent treatment decisions. On this occasion, we 
used marginal structural models to adjust for time-dependent 
confounders, such as the HAQ.8 21 At each follow-up, a logistic 
regression model was used to estimate the probability that the 
patient was receiving the observed treatment. Baseline, previ-
ous and assessment-speciﬁ  c variables were used in the model 
to predict the treatment decisions as outlined in table 1. This 
method aims to include as many potential predictors as possible, 
even if their contribution is small. The reciprocal of the prob-
ability was used if the patient was not receiving treatment at 
that assessment. The product of all the probabilities for each 
patient gave the overall probability of the treatment decisions 
that occurred over the length of follow-up. The inverse of this 
probability (the inverse-probability-of-treatment weight) was 
then used to adjust each patient’s change in HAQ for the vary-
ing treatments and time-dependent confounders. However, 
without a numerator this inverse weight is likely to be highly 
variable and so the inverse-probability-of-treatment weight is 
stabilised.21 The numerator was the product over the length of 
the follow-up of the proportions of patients receiving treatment 
at each assessment.
To allow for loss to follow-up, a stabilised inverse-probability-
of-censoring weight was calculated, based on the same methods 
outlined above. Without adjustment for loss to follow-up, any 
estimate of the change in HAQ in the tenth assessment com-
pleters would be biased. At each assessment, the probability of 
the subject still being in NOAR by the next assessment was esti-
mated using a logistic regression model with the same variables 
as in the treatment decision model. The inverse product of these 
probabilities was also stabilised and this censoring weight was 
multiplied by the stabilised inverse-probability-of-treatment 
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patients not receiving treatment, highlighting the fact that treat-
ment was more likely to be given to patients with more severe 
disease.
Change in HAQ over 10 years and treatment, with 
adjustment by time-dependent confounders
When adjusted for baseline HAQ only, those ever treated with 
DMARD/S had a signiﬁ  cantly greater deterioration in function 
over 10 years, than those never treated (adjusted mean differ-
ence in change (adj_MDIC) in HAQ 0.30, 95% CI 0.18 to 0.42) 
(table 5). However, after adjustment for the time-dependent 
confounders there was no signiﬁ  cant difference in the change in 
HAQ between those ever treated and those not treated (–0.01, 
95% CI –0.20 to 0.19). In other words, after allowing for the fact 
that treatment is more likely to be given to those with severe 
and active IP, treatment has been shown to move patients onto 
a trajectory that they would have followed if they had had 
milder disease not requiring treatment. On adjustment those 
treated early (<6 months) experienced an improvement in func-
tional disability over the 10 years (–0.24, 95% CI –0.58 to 0.09), 
although this was not signiﬁ  cant.
Of the 345 subjects treated over the 10 years, 290 (84%) were 
no longer receiving their ﬁ  rst treatment by 10 years of follow-up. 
Patients who discontinued their ﬁ  rst treatment (either stopped, 
change or added another DMARD/S) within 6 months of start-
ing, experienced a signiﬁ  cant deterioration in functional disabil-
ity (adj_MDIC 0.28, 95% CI 0.04 to 0.52); those who continued 
to receive their ﬁ  rst treatment for >36 months experienced an 
Figure 1  No adjustment for confounders may lead to the incorrect 
inference that those patients who were receiving disease-modifying 
antirheumatic drug treatment at each follow-up experienced poorer 
function, compared with those patients not receiving treatment. HAQ, 
Health Assessment Questionnaire; IP, inﬂ  ammatory polyarthritis.
Table 2  Baseline characteristics of the cohort
Baseline characteristics
IP cohort
(n=1084)
Age at symptom onset (years), median (IQR) 53 (41–66)
Female, n (%) 709 (65.4)
Symptom duration at registration (months), median (IQR) 4 (2–10)
HAQ score, median (IQR)* 0.75 (0.25–1.375)
CRP (mg/dl), median (IQR)† 5 (0–16)
DAS28 score, median (IQR)† 3.93 (2.89–5.01)
Swollen joint count, median (IQR) 6 (2–13)
Tender joint count, median (IQR) 7 (3–16)
Swollen and tender joint count, median (IQR) 3 (0–8)
Satisﬁ  ed 1987 ACR criteria for RA, n (%) 493 (45.5)
Presence of nodules, n (%) 72 (6.6)
Smoking status at baseline, n (%)
  Never smoked 353 (32.6)
 Ex-smoker  ≥10 years 282 (26)
 Ex-smoker  <10 years 161 (14.9)
  Current smoker 288 (26.6)
*HAQ completed by 1072 subjects; †CRP measured on 866 subjects.
ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, 28 joint 
count Disease Activity Score; HAQ, Health Assessment Questionnaire; IP, inﬂ  ammatory 
polyarthritis; RA, rheumatoid arthritis.
Table 3  Disease-modifying antirheumatic drug (DMARD)/steroid treatment received over 10 years of follow-up
Year of follow-up Cohort (n)
Treated between previous and current 
follow-up, n (%)
DMARD/steroid treatment between previous and current follow-up, n (%)
Sulfasalazine (SSZ) Methotrexate (MTX) Steroid (Ss) Other
  0* 1084 226 (21) 135 (60)   15 (7)   72 (32) 17 (8)
  1 1025 450 (44) 283 (63)   69 (15) 139 (31) 36 (8)
  2   961 418 (43) 225 (54)   91 (22) 128 (31) 40 (10)
  3   924 396 (43) 194 (49) 114 (29) 124 (31) 38 (10)
  5   855 374 (44) 164 (44) 144 (39) 127 (34) 32 (9)
  7   732 305 (42) 113 (37) 150 (49)   98 (32) 25 (8)
10   664 293 (44) 108 (37) 159 (54)   95 (32) 22 (8)
Year of follow-up Cohort (n) Ever treated by follow-up, n (%)
Ever DMARD/steroid treatment by follow-up, n (%)
Sulfasalazine (SSZ) Methotrexate (MTX) Steroid (Ss) Other
  0 1084 226 (21) 135 (60)   15 (7)   72 (32) 17 (8)
  1 1025 453 (44) 285 (63)   70 (15) 139 (31) 41 (9)
  2   961 464 (48) 298 (64) 101 (22) 151 (33) 56 (12)
  3   924 466 (50) 308 (66) 134 (29) 156 (33) 60 (13)
  5   855 444 (52) 294 (66) 170 (38) 161 (36) 64 (14)
  7   732 374 (51) 255 (68) 182 (49) 142 (38) 58 (16)
10  664 361 (54) 255 (71) 192 (53) 142 (39) 62 (17)
*Treated since symptom onset to baseline.
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Table 4  Health Assessment Questionnaire (HAQ) at baseline, 10 years and difference over 10 years, by time to, and 
time receiving, treatment
  n (%)
Baseline HAQ
Median (IQR)
10 Year HAQ
Median (IQR)
Change over 10 
years 
Mean (95% CI)
Not treated over 
follow-up
297 (46) 0.50 (0.13–0.88) 0.50 (0.13–1.25) 0.13 (0.05 to 0.21)
Treated over follow-up 345 (54) 1.00 (0.50–1.50) 1.38 (0.50–2.00) 0.24 (0.14 to 0.33)
Time to ﬁ  rst treatment
  <6 Months 122 (35) 1.25 (0.63–1.75) 1.25 (0.25–2.13) 0.00 (–0.17 to 0.17)
  6–12 Months   76 (22) 1.00 (0.44–1.63) 1.50 (0.50–2.00) 0.28 (0.08 to 0.48)
  >12 Months 147 (43) 0.75 (0.38–1.38) 1.38 (0.63–2.00) 0.41 (0.28 to 0.54)
Time receiving ﬁ  rst treatment
  ≤6 Months   91 (26) 1.00 (0.38–1.50) 1.63 (0.50–2.13) 0.35 (0.15 to 0.55)
  >6 to ≤36 Months 123 (36) 1.00 (0.38–1.63) 1.38 (0.63–2.00) 0.24 (0.10 to 0.38)
  >36 Months 131 (38) 0.88 (0.50–1.50) 1.25 (0.25–1.88) 0.16 (0.002 to 0.32)
Time receiving any treatment over 10 years
  ≤48 Months   88 (26) 0.88 (0.25–1.50) 0.88 (0.06–1.63) 0.06 (–0.12 to 0.25)
  >48 to ≤96 Months   57 (17) 0.88 (0.38–1.63) 1.50 (0.63–2.00) 0.38 (0.13 to 0.63)
  >96 Months 200 (58) 1.00 (0.50–1.56) 1.50 (0.63–2.13) 0.27 (0.15 to 0.39)
Table 5  Mean difference in change in Health Assessment Questionnaire (HAQ) over 10 years by time to, and time 
receiving, treatment—adjusted by baseline HAQ and marginal structural weight
  n
Difference in change in HAQ between baseline and year 10, 
compared with never treated
Adjusted by baseline HAQ
Adjusted by marginal structural 
weight
Mean (95% CI) Mean (95% CI)
Treated over follow-up 345   0.30 (0.18 to 0.42) –0.01 (–0.20 to 0.19)
Time to ﬁ  rst treatment
  <6 Months 122   0.13 (–0.04 to 0.3) –0.24 (–0.58 to 0.09)
  6–12 Months   76   0.35 (0.15 to 0.54)   0.12 (–0.13 to 0.37)
  >12 Months 147   0.39 (0.24 to 0.54)   0.18 (–0.06 to 0.41)
Effect of ﬁ  rst treatment duration
  ≤6 Months   91   0.41 (0.23 to 0.59)   0.28 (0.04 to 0.52)
  >6–≤36 Months 123 –0.10 (–0.31 to 0.1) –0.25 (–0.56 to 0.06)
  >36 Months 131 –0.10 (–0.28 to 0.09) –0.37 (–0.77 to 0.04)
Effect of treatment duration over 10 years
  ≤48 Months   88   0.08 (–0.1 to 0.26) –0.21 (–0.62 to 0.21)
  >48–≤96 Months   57   0.35 (0.1 to 0.6)   0.53 (–0.01 to 1.06)
  >96 Months 200 –0.07 (–0.29 to 0.15) –0.37 (–0.77 to 0.04)
Effect per number of months of ﬁ  rst treatment
  No of months treated in ﬁ  rst 6 months since 
 symptom  onset
— –0.09 (–0.15 to –0.03) –0.09 (–0.17 to –0.01)
  No of months treated after ﬁ  rst 6 months since 
 symptom  onset
— –0.002 (–0.004 to 0.0001) –0.004 (–0.01 to –0.0004)
Effect per number of months of treatment over 10 years
  No of months treated in ﬁ  rst 6 months since 
 symptom  onset
— –0.10 (–0.16 to –0.04) –0.10 (–0.19 to –0.02)
  No of months treated after ﬁ  rst 6 months since 
 symptom  onset
—   0.003 (0.001 to 0.005)   0.001 (–0.002 to 0.005)
improvement (adj_MDIC –0.37, 95% CI –0.77 to 0.04), although 
this was not signiﬁ  cant.
Of the 642 subjects who had completed a HAQ both at base-
line and at the 10 year assessment, 497 (77.4%) satisﬁ  ed the 
ACR criteria for RA cumulatively over the 10 years of follow-up. 
Of these subjects, 316 (64%) had been treated by 10 years, of 
whom 110 (35%) were treated within 6 months of symptom 
onset. The results in table 5 were very similar when conﬁ  ned to 
those who satisﬁ  ed the ACR criteria for RA cumulatively over 
the 10 years of follow-up (data not shown).
The impact of early treatment on long-term functional dis-
ability is further highlighted by the signiﬁ  cant beneﬁ  t from each 
additional month of early treatment, be that the ﬁ  rst DMARD/S 
(adj_MDIC –0.09, 95% CI –0.17 to –0.01) or any subsequent 
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treatment within the ﬁ  rst 6 months of symptoms (adj_MDIC 
–0.10, 95% CI –0.19 to –0.02). Furthermore, a signiﬁ  cant ben-
eﬁ  t from each additional month of the continuation of the ﬁ  rst 
treatment past 6 months was found (adj_MDIC –0.004, 95% CI 
–0.01 to –0.0004).
DISCUSSION
The results of this analysis have three important clinical mes-
sages. The ﬁ  rst is that the beneﬁ  ts of early DMARD/S treat-
ment in patients with IP are still apparent after 10 years of 
follow-up. Even in the unadjusted analysis, those who started 
their ﬁ  rst DMARD/S within 6 months of symptom onset had 
no overall deterioration in HAQ, whereas those who started 
treatment later experienced deterioration. When adjusted for 
baseline disease severity and subsequent treatment decisions, 
those treated early experienced a non-signiﬁ  cant  improve-
ment in change in function compared with those judged by 
their clinicians not to require DMARD/S at all (adj_MDIC in 
HAQ –0.24, 95% CI –0.58 to 0.09); and a signiﬁ  cant beneﬁ  t 
from each additional month of treatment within 6 months 
of the onset of symptoms (adj_MDIC –0.10, 95% CI –0.19 
to –0.02). This provides still further evidence of a ‘window 
of opportunity’ for optimal beneﬁ   t from the introduction 
of DMARD/S and that early referral to a rheumatologist is 
justiﬁ  ed.23
We have previously reported the beneﬁ  t of early treatment 
with respect to physical function at 5 years in the NOAR 
cohort.9 In that analysis we used the propensity score method 
to adjust for baseline disease activity and thus confounding by 
indication. This showed the beneﬁ  t of early treatment regard-
less of subsequent treatment duration. In this new analysis we 
test the hypothesis that the time receiving ﬁ  rst treatment is also 
an important prognostic indicator. We found that patients who 
discontinued their ﬁ  rst DMARD/S within 6 months experienced 
a signiﬁ  cant deterioration in long-term functional ability, irre-
spective of subsequent treatment decisions (adj_MDIC in HAQ 
0.28, 95% CI 0.04 to 0.52). This has important implications for 
the future treatment of patients with IP. For example, presently 
in the UK, anti-tumour necrosis factor treatment is only recom-
mended for patients for whom two or more DMARD/S have 
failed.24 Our results suggest that patients who fail to respond 
to, or cannot tolerate, their ﬁ  rst DMARD/S are likely to have a 
poor long-term outcome and that it may be appropriate to con-
sider more aggressive treatment at this stage rather than wait for 
another DMARD/S to fail.
The third clinical message is that the total duration of 
DMARD/S over the ﬁ  rst 10 years of disease has an important 
impact on functional outcome. Patients who received a total 
duration of treatment >8 years experienced an improvement in 
function compared with those never treated (adj_MDIC in HAQ 
–0.37; 95% CI –0.77 to 0.04). Other studies have also shown 
that the beneﬁ  t of early treatment is not sustained unless that 
treatment is continued. For example, a randomised controlled 
trial in the Netherlands found clinical and radiological beneﬁ  t 
at 12 months in those randomised to early aggressive treatment 
compared with the pyramid approach.25 However, in the 5-year 
follow-up of this cohort these differences did not persist.26 As 
the treatment strategies were not continued during follow-up, 
the authors conclude that early aggressive treatment should be 
continued into the long term.
Inevitably, a 10-year follow-up study reﬂ  ects the changing 
prescribing practice over the period of follow-up. Patients in 
this study were recruited in the early 1990s when SSZ mono-
therapy was the usual ﬁ  rst DMARD. However, even though the 
treatment strategies in the 1990s were less aggressive than those 
used today, we were still able to show a beneﬁ  t of early and 
sustained treatment. It is likely that the beneﬁ  t will be greater 
with the use of MTX and combination therapy much earlier in 
the disease course.
Until recently there were relatively few treatment options for 
patient with IP and RA and treatment goals were less ambitious 
than they are now. Therefore clinicians continued to prescribe 
a treatment even if there was only minor improvement so long 
as no adverse events were seen. Many studies looked at drug 
survival rates as an outcome in itself,27–29 rather than the sub-
sequent consequences of treatment persistence on patient out-
comes, as we have done here. The current strategy of targeting 
remission or low-disease activity results in the faster changing 
of DMARDs and so shortening of times on any particular treat-
ment. Thus, the association between the time receiving the ﬁ  rst 
treatment and functional disability may be stronger in patients 
presenting now. A pooled analysis of MTX and anti-anti-tumour 
necrosis factor clinical trials of patients with early RA found that 
disease activity at baseline and particularly at 3 months (ie, early 
treatment response) was signiﬁ  cantly related to disease activity 
after 1 year.30 We would have liked to have explored the conse-
quences of treatment strategies on radiological progression. We 
have previously shown that treating patients within 6 months 
of IP symptom onset has a beneﬁ  cial effect on radiological pro-
gression10 at 5 years. However x-ray examinations were not 
undertaken on all subjects at the tenth assessment, therefore 
radiological progression by 10 years’ follow-up could not be 
analysed.
Our study has a number of strengths and weaknesses. It uses 
a primary care-based inception cohort of patients followed up 
systematically over a 10-year period. Patients were recruited 
with IP rather than RA. We have therefore been able to include 
patients who do not satisfy the ACR criteria for RA at baseline 
but do satisfy them subsequently. The results should therefore 
have good generalisability. Some rheumatologists might con-
sider the inclusion of subjects with RA, IP, psoriatic arthritis or 
postviral arthritis as patients with different disease course and 
treatment strategies. However, the marginal structural models 
approach adjusts for the differences in disease severity and treat-
ment over time which might be seen in the different conditions. 
Furthermore, the restriction in the analysis in table 4 to those 
497 patients (77% of those who had 10 year follow-up) who 
cumulatively satisﬁ  ed the ACR criteria for RA, produced results 
similar to that for the whole IP cohort.
Adjusting for a series of treatment decisions and ﬂ  uctuating 
disease activity over 10 years is complex, particularly as patients 
were seen at predeﬁ  ned time intervals and not speciﬁ  cally at the 
time of ﬂ  ares or treatment change. A variety of methods have 
been suggested including propensity scores,31 as we have used 
previously.9 10 In this study, we used marginal structural mod-
els as they are the only method which adjusts for time-varying 
  confounders. This method has only been used previously once 
in RA research.8 There is a debate as to which variables should 
be included in the models.32 In accordance with the recommen-
dations of Rubin33 and Robins et al34 we included variables even 
with weak effects on outcome (although strong associations 
with treatment) in order to minimise bias. Results from simula-
tion experiments32 suggest that variables related to outcome but 
not to treatment should always be included as they decrease the 
variance of estimates without increasing bias. However, the pos-
sibility of residual confounding remains owing to unmeasured 
variables that are associated either with treatment decisions or 
with outcome. While we included variables that cover the full 
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spectrum of disease activity, previous treatment and comorbid-
ity, unmeasured confounders might include patient preferences 
and compliance.
In summary we have demonstrated the importance of time to 
ﬁ  rst DMARD/S treatment, response to ﬁ  rst DMARD/S and total 
duration of DMARD treatment over a 10-year time period in 
patients with early IP using state-of-the-art statistical methods 
to adjust for time varying confounding.
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